Search - tctmd.com

Displaying 241 - 260 of 344

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

News Daily News

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

Todd Neale

August 17, 2018

News Daily News

TRIUMPH in Print: Triple-Drug Polypill Shines for Fast, Safe Blood Pressure Reduction

Shelley Wood

August 15, 2018

News Daily News

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

Michael O'Riordan

July 16, 2018

News Conference News CRT 2018

Radial Access PCI Reduces Risk of Mortality and Bleeding in VALIDATE-SWEDEHEART

Michael O'Riordan

March 06, 2018

News Daily News

Roughly Half of Obese Patients Who Have Bariatric Surgery Are Off Type 2 Diabetes Meds at 6 Years

Michael O'Riordan

February 19, 2018

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

Todd Neale

January 25, 2018

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Presentation TCT 2017

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

Presenter: Thomas F. Luscher, David Erlinge

October 31, 2017

Presentation TCT 2017

VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI

Presenter: Y. S. Chandrashekhar, David J. Moliterno, Stefan K. James

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Shelley Wood

August 27, 2017

Presentation ESC 2017

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Presenter: David Erlinge

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

Study Suggests VKA Monotherapy Sufficient in Patients With A-fib but No CAD

Yael L. Maxwell

June 20, 2017

News Daily News

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

Shelley Wood

February 24, 2017

Advertisement

TCTMD’s Top 10 Most Popular Stories for August 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

TRIUMPH in Print: Triple-Drug Polypill Shines for Fast, Safe Blood Pressure Reduction

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

Radial Access PCI Reduces Risk of Mortality and Bleeding in VALIDATE-SWEDEHEART

Roughly Half of Obese Patients Who Have Bariatric Surgery Are Off Type 2 Diabetes Meds at 6 Years

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI

Rationale and Studies of P2Y12 Inhibitor Monotherapy

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Study Suggests VKA Monotherapy Sufficient in Patients With A-fib but No CAD

Four-in-One Blood Pressure Pill Shows Promise as Initial Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content